SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Clinical trials for SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS trials appear
Sign up with your email to follow new studies for SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could ease severe childhood arthritis
Disease control Recruiting nowThis study tests a new oral medication, upadacitinib, in children aged 1 to 17 with active systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that can affect the whole body. About 90 participants will receive either upadacitinib or the standard in…
Matched conditions: SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with arthritis: Long-Term drug study launches
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the d…
Matched conditions: SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New study tracks ilaris use in rare inflammatory diseases across europe
Disease control Recruiting nowThis study looks at how patients with Familial Mediterranean Fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis and adult-onset Still's disease) use the drug canakinumab (Ilaris) over the long term. Researchers will track 160 patients across Europe …
Matched conditions: SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kids with rare arthritis: drug dose study underway
Disease control Recruiting nowThis study is for children and teens aged 1 to 17 with systemic juvenile idiopathic arthritis (sJIA), a condition that causes joint swelling and fever. Researchers are testing different doses of the drug sarilumab to find the best amount that works and is safe. The study involves…
Matched conditions: SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Scientists launch deep dive into mysterious inflammatory diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) by observing up to 2,000 participants over time. Researchers will collect medical history, blood samples, and genetic data to identify …
Matched conditions: SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC